1. Medtech Insight
  2. >>Device Area
  3. >>Neurology

Medtronic’s Solitaire Gets STRATIS Real-World Stroke Boost

 
• By Reed Miller

Registry data presented at the International Stroke Conference confirm that mechanical thrombectomy with Medtronic’s Solitaire stent retriever can be safely performed in community hospitals as effectively as it was in the randomized trials observed in randomized trials. The results also show that the benefits of transferring a patient with an acute ischemic stroke to a comprehensive stroke center are usually not worth the extra time it takes to transport the patient there.

CT Scan-Brain_1200x675

Results from the STRATIS registry shows that community hospitals can treat acute stroke patients with mechanical thrombectomy using Medtronic PLC’s Solitaire stent retriever as effectively as comprehensive stroke centers at teaching hospitals. The study found that the benefits of transferring these patients to specialized centers is outweighed by the potential for additional brain damage that can result from the extra time it takes to get there.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurology

New Treatment For Chronic Facial Pain Could Launch By Fall 2025

 
• By Elizabeth Orr

NeuroOne is preparing to submit its OneRF Trigeminal Nerve Ablation System to the US FDA for treating trigeminal neuralgia, a chronic facial pain condition. CEO Dave Rosa told Medtech Insight that he expects a possible product launch by fall 2025.

Q’Apel Medical Recalls, Discontinues Stroke Therapy System After FDA Warning Letter, Class I Designation

 
• By Brian Bossetta

Q’Apel Medical has pulled its aspiration system for stroke thrombectomy from the market after concerns raised by the US FDA in a February warning letter.

Biolinq’s $100M In Series C Financing Supports Efforts To Bring Diabetic Glucose Monitoring With Needle-Free Patch To Market

 
• By Marion Webb

Biolinq plans to use the proceeds of its new venture funding to support US FDA de novo review, automation engineering and commercialization efforts with partners, CEO Rich Yang told Medtech Insight.

FDA Issues A Pair Of Early Alerts For Intravascular Catheters

 
• By Brian Bossetta

The US FDA continues to issue early alerts as part of its communications pilot aimed at improving how the agency manages recalls. This time, the agency is notifying users about two separate intravascular catheters.

More from Device Area